Skip to main content
Clinical Trials

S1605, Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (CTMS# 18-0014)

Cancer Type

Urinary Bladder

ClinicalTrials.gov Identifier

NCT02844816

Principal Investigator

John Sarantopoulos MD

For more information about this study
View Details

About This Study

This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.